Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10918591 | Radiotherapy and Oncology | 2014 | 6 Pages |
Abstract
We observed significantly less BCF and LF in the high-dose arm. This suggests improvement of the therapeutic ratio. However, we observed similar rates of CF and PCD at the current update. More follow-up is needed to investigate which patients benefit in terms of prolonged OS.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Wilma D. Heemsbergen, Abrahim Al-Mamgani, Annerie Slot, Michel F.H. Dielwart, Joos V. Lebesque,